ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT, OR TO BE ACCESSED BY, PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH ANY CONSENT OR OTHER FORMALITY WHICH SKYEPHARMA PLC REGARDS AS UNDULY ONEROUS.
You are attempting to enter the area of this website that is designated for the publication of announcements, documents and information (together, the "Information") in connection with the recommended all share merger between Vectura Group plc ("Vectura") and Skyepharma PLC ("Skyepharma") (the "Merger"). The Information is made available in good faith and for information purposes only and is subject to the terms and conditions set out below. In particular, the Information is not intended to, and does not, constitute or form part of an offer to sell or otherwise dispose or subscribe for any securities pursuant to the Merger or otherwise in any jurisdiction in which such offer or solicitation is unlawful.
Access to the Information
If you would like to access the Information, please read this notice carefully. This notice applies to all persons who view this area of the website and, depending on where you are located, may affect your rights or responsibilities. Skyepharma reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of Skyepharma.
The Information is not for release, publication or distribution, directly or indirectly, in or into any jurisdiction where to do so would violate the law of that jurisdiction (a "Restricted Jurisdiction"), and accordingly, viewing the Information may not be lawful if you are resident or located in a Restricted Jurisdiction. In certain jurisdictions, including Restricted Jurisdictions, only certain categories of person may be allowed to view the Information. Any person resident or located outside the United Kingdom who wishes to view the Information must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction.
If you are resident or located in a Restricted Jurisdiction, whether or not subject to making certain notifications or taking other action, you should not view this area of the website. Similarly, the Information is not being, and must not be, released or otherwise forwarded, distributed or sent in or into a Restricted Jurisdiction and persons receiving such Information (including custodians, nominees and trustees) must not distribute or send it in, into or from a Restricted Jurisdiction.
Forward Looking Statements
The Information may contain certain "forward-looking statements" regarding the financial position, business strategy or plans for future operations of Skyepharma. All statements other than statements of historical fact included in any document may be forward-looking statements. Forward-looking statements also often use words such as "believe", "expect", "estimate", "intend", "anticipate" and words of a similar meaning. By their nature, forward-looking statements involve risk and uncertainty that could cause actual results to differ materially from those suggested by them. Much of the risk and uncertainty relates to factors that are beyond the relevant companies' abilities to control or estimate precisely, such as future market conditions and the behaviours of other market participants, and therefore undue reliance should not be placed on such statements which speak only as of the date of the document in which it is contained. Skyepharma does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law or regulation.
Unless expressly stated otherwise, no statement contained or referred to in this area of the website is intended to constitute a profit forecast for any period and no statement should be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Skyepharma or Vectura, as appropriate.
The only responsibility accepted by the directors of Skyepharma in relation to the Information is for the correctness and fairness of its reproduction or presentation, unless the responsibility statement in any relevant document expressly provides otherwise.
None of Skyepharma, the directors of Skyepharma nor any of Skyepharma's affiliated companies, has reviewed, and none of them is responsible for, or accepts any liability in respect of, any information contained on any other website which may be linked to or from this website by a third party.
The Information speaks only at the date of the relevant document and neither Skyepharma nor any of its affiliated companies has, and accepts, any responsibility or duty to update any Information (other than to the extent such duty arises as a matter of law or regulation).
THE INFORMATION MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON EITHER IN WHOLE OR IN PART WHERE TO DO SO WOULD OR MAY CONSTITUTE A BREACH OF ANY APPLICABLE LOCAL LAWS OR REGULATIONS.
Electronic versions of the Information are not directed at or accessible by persons resident in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.
If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) or, if you are located outside the UK, from an appropriately authorised independent financial adviser.
Lazard & Co., Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as financial adviser for Skyepharma and no one else in connection with the Merger and will not be responsible to anyone other than Skyepharma for providing the protections afforded to clients of Lazard & Co., Limited nor for providing advice in relation to any matter relating to the Merger. Neither Lazard & Co., Limited nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lazard & Co., Limited in connection with the Merger.
This notice shall be governed by and construed in accordance with English law.
Confirmation of understanding and acceptance
In order to view the Information, by clicking on "CONFIRM" below, you are making the following confirmations:
- I have read and understood the notice set out above and agree to be bound by its terms;
- I intend to access this area of the website for information purposes only;
- I am a resident of or located in the United Kingdom or another jurisdiction into which the distribution of the Information does not constitute a violation of the relevant laws of such jurisdiction and I am not acting on behalf of someone who is resident or located in a Restricted Jurisdiction; and
- I will not copy, forward, transfer or distribute (by any means including by electronic transmission) the Information to any person who is resident or located in a Restricted Jurisdiction.
If you are not able to give these confirmations (as applicable), you should click on "DECLINE" below and we cannot provide you with access to the Information.